+ Filter



Fibronectin

Anti-fibronectin Products
-
- Derivation: Human
- Type: IgG
- Application: WB, Neut, FuncS
- Recombinant Anti-fibronectin Antibody (MOB-361)
-
- Derivation: Mouse
- Type: IgG
- Application: WB, ELISA, IHC, FuncS
- Mouse Anti-Fibronectin Recombinant Antibody (clone FDB3) (HPAB-0015LY)
-
- Type: Mouse IgG
- Application: WB
- Mouse Anti-Fibronectin Antibody, mRNA (HPAB-0015LY-mRNA) (HPAB-0015LY-mRNA)
-
- Recombinant Anti-fibronectin Antibody Fab Fragment (MOB-361-F(E))
-
- Derivation: Mouse
- Type: Fab
- Application: FC, WB, FuncS
- Recombinant Anti-fibronectin Antibody scFv Fragment (MOB-361-S(P))
-
- Derivation: Mouse
- Type: scFv
- Application: ELISA, WB, IP, FuncS
- Recombinant Human Anti-fibronectin Antibody Fab Fragment (MHH-361-F(E))
-
- Derivation: Human
- Type: Fab
- Application: WB, FC, FuncS
- Recombinant Human Anti-fibronectin Antibody scFv Fragment (MHH-361-S(P))
-
- Derivation: Human
- Type: scFv
- Application: IP, IF, Biosensors, FuncS
- Chicken Anti-Fibronectin Polyclonal IgY (BRD-0970MZ)
-
- Species Reactivity: Human, Mouse, Rat
- Type: Chicken antibody
- Application: ELISA, WB
-
- Species Reactivity: Human
- Type: Rabbit IgG
- Application: ELISA, WB, IP
-
- Species Reactivity: Human, Mouse, Chicken
- Type: Mouse IgM
- Application: ELISA, IHC, IP, IF, WB
More Infomation
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
More Infomation
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
The fibronectins (FNs) comprise a group of extracellular matrix proteins that mediate cell adhesion, migration, proliferation, and differentiation. Diversity in the FNs occurs by alternative splicing in two type III repeats termed EIIIA (or ED-A) and EIIIB (or ED-B) and one non-homologous repeat called V (or IIICS). The EIIIA and EIIIB segments are either entirely included or excluded, whereas the V region may be included, excluded, or partially included in FN.
